ERBB2 and colorectal carcinoma: Treatment of CRC cells with recombinant TRAIL was further reported to lead to EGFR upregulation and shedding of TGF-α, resulting in the activation of autocrine and paracrine EGFR/HER2 pro-survival signaling [39].